De­spite a PhI­II fail, Bio­gen push­es ALS drug tofersen for­ward with new analy­sis in move echo­ing Aduhelm

In a move rem­i­nis­cent of its ad­u­canum­ab de­vel­op­ment plans, Bio­gen is tak­ing steps Fri­day to try to paint a failed Phase III in a pos­i­tive light — this time for ALS.

The big bio­phar­ma re­leased a new analy­sis com­bin­ing Phase III da­ta with re­sults from an open-la­bel ex­ten­sion on the Io­n­is-part­nered an­ti­sense drug tofersen. Bio­gen says the drug proved more ef­fec­tive for pa­tients who start­ed tak­ing it ear­li­er in their dis­ease, with the new analy­sis sug­gest­ing a clin­i­cal func­tion ben­e­fit and longer sur­vival times.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER